|4Dec 15, 5:09 PM ET

Harsch Mutya 4

4 · VYNE Therapeutics Inc. · Filed Dec 15, 2023

Insider Transaction Report

Form 4
Period: 2023-12-13
Harsch Mutya
CHIEF LEGAL OFFICER AND GC
Transactions
  • Award

    Common Stock

    2023-12-13+62,50087,096 total
  • Award

    Stock Option (right to buy)

    2023-12-13+62,50062,500 total
    Exercise: $2.70Exp: 2033-12-12Common Stock (62,500 underlying)
Footnotes (3)
  • [F1]Grant to the Reporting Person of a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
  • [F2]The shares underlying the RSU vest over a period of 4 years. 25% of the shares subject to the award will vest on December 31, 2024 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
  • [F3]The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on December 31, 2024 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION